Drug Profile
Research programme: monoclonal antibody therapies - Biocon/Vaccinex
Alternative Names: BVX-10; BVX-10 antibody; BVX10 MAbLatest Information Update: 10 Oct 2016
Price :
$50
*
At a glance
- Originator Biocon; Vaccinex
- Class Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 10 Oct 2016 Discontinued - Preclinical for Inflammation in India and USA (Parenteral)
- 14 Oct 2011 Preclinical development is ongoing in India and the USA
- 10 Apr 2007 Preclinical development is ongoing in Cancer and Inflammation